![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Objective
Shenkang injection (SKI) has been widely used in China for many years for the treatment of kidney disease. The objective of this systematic review was to assess the efficacy of Shenkang injection for the treatment of acute kidney injury (AKI).
Methods
A search was conducted across seven databases, encompassing data from the inception of each database through October 8th, 2023. Randomized controlled trials comparing SKI-treated AKI patients with control subjects were extracted. The main outcome measure was serum creatinine (SCr) levels. Secondary outcomes included blood urea nitrogen (BUN), serum cystatin C (CysC), 24-h urine protein (24 h-Upro) levels, APACHE II score and adverse reactions.
Results
This meta-analysis included eleven studies, and the analysis indicated that, compared with the control group, SKI significantly decreased SCr [WMD = −23.31, 95% CI (-28.06, −18.57); p < 0.001]; BUN [WMD = −2.07, 95% CI (-2.56, −1.57); p < 0.001]; CysC [WMD = −0.55, 95% CI (-0.78, −0.32), p < 0.001]; 24-h urine protein [WMD = −0.43, 95% CI (-0.53, −0.34), p < 0.001]; and the APACHE II score [WMD = −3.07, 95% CI (-3.67, −2.48), p < 0.001]. There was no difference in adverse reactions between the SKI group and the control group [RR = 1.32, 95% CI (0.66, 2.63), p = 0.431].
Conclusion
The use of SKI in AKI patients may reduce SCr, BUN, CysC, 24-h Upro levels, and APACHE II scores in AKI patients. The incidence of adverse reactions did not differ from that in the control group. Additional rigorous clinical trials will be necessary in the future to thoroughly evaluate and establish the effectiveness of SKI in the treatment of AKI.
Author contributions
SL and CY initiated the study and participated in its design. SL and SW were responsible for the study selection, data extraction and analysis. SL and YC wrote the manuscript. CY oversawed all aspects of the study. CW guided the revision of the paper in response to the reviewer comments in the major revision. All of the authors contributed to the article and provided their approval for the submitted version.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Data availability statement
The study contains original contributions that are included in the article/supplementary material. For additional information, please contact the corresponding author.